WA
IMGN

Waverly Advisors’s Immunogen Inc IMGN Stock Holding History

Waverly Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-161
Closed -$2K – 699
2014
Q3 		$2K Hold
161
– – ﹤0.01% 735
2014
Q2 		$2K Hold
161
– – ﹤0.01% 701
2014
Q1 		$2K Hold
161
– – ﹤0.01% 668
2013
Q4 		$2K Buy
+161
New +$2.47K ﹤0.01% 792

Other funds holding IMGN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Waverly Advisors's IMGN Position: Q4 2014 in Review

Waverly Advisors sold out of Immunogen Inc (IMGN) in Q4 2014, closing a stake of 161 shares — an estimated $2K sold.

Waverly Advisors first reported a position in IMGN in Q4 2013 and held it in 4 quarters. The position peaked at $2K in Q3 2014. 131 funds tracked by Wall St. Rank hold IMGN as of Q4 2014.

  • Waverly Advisors reported no remaining Immunogen Inc position as of Q4 2014 after selling out during the quarter.
  • Waverly Advisors sold 161 Immunogen Inc shares in Q4 2014, an estimated $2K.
  • Waverly Advisors first reported a position in Immunogen Inc in Q4 2013 and held it in 4 quarters.
  • Waverly Advisors's Immunogen Inc position peaked at $2K in Q3 2014.
  • 131 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2014.

Based on Waverly Advisors's 13F filing for Q4 2014, filed 15 Jan 2015.